Dr. Reddy’s Laboratories reports $853M revenue but falls on weak earnings and U.S. tariff risks for generics.
Dr. Reddy’s Laboratories (RDY) slid approximately 7% after its fiscal Q1 2027 results underwhelmed investors. The company posted $853M in revenue for the quarter, surpassing some estimates but failing to offset broader concerns.
The decline follows President Donald Trump’s threat to impose new tariffs on the generics industry, adding pressure to Indian drugmakers. Prior quarter revenue stood at $820M, with consensus expectations slightly below the reported figure.
Shares extended losses as traders weighed the combined impact of earnings and trade policy risks.